論文・出版
JBCRGのあらたな取り組み -JCBRGの設立と経緯および臨床試験への取り組み
大野真司
医学のあゆみ. 2017 May; 261(5): 572-576.
Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (JBCRG-C01)
Hiroyasu Yamshiro · Hiroji Iwata · Norikazu Masuda · Naohito Yamamoto · Reiki Nishimura · Shoichiro Ohtani · Nobuaki Sato · Masato Takahashi · Takako Kamio · Kosuke Yamazaki · Tsuyoshi Saito · Makoto Kato · Tecchuu Lee · Shinji Ohno · Katsumasa Kuroi · Toshimi Takano · Masahiro Takada · Shinji Yasuno · Satoshi Morita · Masakazu Toi
International Journal of Clinical Oncology. 2015 Aug; 20(4): 709-722.
https://doi.org/10.1007/s10147-015-0785-8
ネオアジュバント化学療法後の再発リスクが高いホルモン受容体陽性HER2陰性原発性乳癌患者を対象としたサイクリン依存性キナーゼ（CDK）4/6阻害薬palbociclib（PD-0332991）を評価する第III相試験「PENLOPE試験」
岩田 広治
Cancer Board 乳癌. 2014 Dec; 7(2).
ホルモン陽性HER2陰性進行再発乳癌に対する、ホルモン療法による維持療法を利用したベバシズマブ＋パクリタキセル療法の治療最適化研究 JBCRG-M04（BOOSTER）
佐治重衡、戸井雅和
Cancer Board 乳癌. 2014 Dec; 7(2).
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
Norikazu Masuda, Kenji Higaki, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani, Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi
Cancer Chemotherapy and Pharmacology. 2014 Aug; 74(2): 229-38.
https://doi.org/10.1007/s00280-014-2492-y
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)
Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yoichi Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita & Masakazu Toi on behalf of the JBCRG-C03 Collaborative Group
Breast Cancer Research and Treatment. 2014 May; 145(1): 143-53.
https://doi.org/10.1007/s10549-014-2907-9
Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study
Yoshiki Mikami, Takayuki Ueno, Kenichi Yoshimura, Hitoshi Tsuda, Masafumi Kurosumi, Shinobu Masuda, Rie Horii, Masakazu Toi and Hironobu Sasano
Cancer Science. 2013 Nov; 104(11): 1539–1543.
https://doi.org/10.1111/cas.12245
An Overview of the Japan Breast Cancer Research Group (JBCRG) activities
Shinji Ohno, Katsumasa Kuroi and Masakazu Toi
Breast Cancer. 2013 Oct; 20(4): 291-5.
https://doi.org/10.1007/s12282-012-0420-8
JBCRG (Japan Breast Cancer Research Group)の現況と展望
増田慎三、戸井雅和、黒井克昌他
日本臨床. 2012; 70(7): 763-771.
Neo-LaTH試験（HER2陽性乳癌におけるDual-HER2 blockage療法ホルモン療法の検討：ランダム化第Ⅱ相試験）
増田慎三、戸井雅和、笠井宏委
Cancer Board 乳癌. 2012; 5(2): 71-73.